



## Synaptic Dysfunction in Neurological Diseases

Guest Editor:

### Dr. Rachid El Fatimy

1. Mohammed VI Polytechnic University, Benguerir, Morocco
2. Ann Romney Center of Neurologic Diseases, Harvard Medical School, Brigham and Women's Hospital, Boston, MA, USA

Deadline for manuscript submissions:

**closed (28 February 2021)**

### Message from the Guest Editor

Dear Colleagues,

We are pleased to announce a Special Issue in the topic of “Synaptic Dysfunction in Neurological Diseases” in *Pharmaceuticals* journal. The complexity of brain functions is linked to the accelerated evolution of synapses. Synapses can operate with a certain degree of autonomy from the cell body, and their outstanding complexity results in a great variety of possible synaptic alterations. Synaptic dysfunction can result either from alterations in their intrinsic synaptic molecular mechanisms, or be secondary to changes in additional biochemical processes in the surrounding environment. Many psychiatric and neurologic disorders are accompanied by alterations in spine morphology, synapse number, signaling dysfunction, and/or changes in localized translation. This Special Issue aims to decipher all research on aberrant synapse physiology, by describing how dysregulation in synapse biology contributes to the pathogenesis of neurological diseases, and may directly contribute to neurodevelopmental disorders and neurodegenerative disorders, as well as psychiatric diseases.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

## Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

*Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Pharmaceutical Science*)

## Contact Us

*Pharmaceuticals* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/pharmaceuticals](http://mdpi.com/journal/pharmaceuticals)  
[pharmaceuticals@mdpi.com](mailto:pharmaceuticals@mdpi.com)